Is Gilead Sciences, Inc. a Buy?
With only a few weeks remaining in 2017, Gilead Sciences (NASDAQ: GILD) stock price appears to be on course to finish roughly at the same level that it began the year. After getting off to a rocky start, the biotech's share price gained significant momentum beginning in June thanks to better-than-expected second-quarter results and an acquisition of Kite Pharma. However, the euphoria faded in the fourth quarter.
Is Gilead Sciences a smart pick for investors now? The best way to answer the question is to evaluate the reasons for investing in the biotech and weigh them against the reasons not to buy it.
Image source: Getty Images.
Source: Fool.com
Gilead Sciences Inc Aktie
67,16 €
0,43 %
Die Community neigt bei Gilead Sciences Inc zu Buy-Einschätzungen, mit einigen mehr als Sell-Einschätzungen.
Das Kursziel von 84 € für Gilead Sciences Inc weist auf eine Steigerung von über 20% gegenüber dem aktuellen Kurs von 67.16 € hin.
